Rsv

Pfizer acquires RSV therapeutic candidates

07-Apr-2022 By Rachel Arthur

Pfizer will acquire ReViral, a privately-held clinical-stage company which is focused on novel antiviral therapeutics for respiratory syncytial virus (RSV), for up to $525m.

Moderna initiates Phase 3 trial for RSV vaccine candidate

22-Feb-2022 By Rachel Arthur

Moderna has initiated the Phase 3 portion of its pivotal respiratory syncytial virus (RSV) vaccine trial: looking towards its ultimate goal to combine the vaccine with its COVID-19 and flu boosters into a single dose booster.

Pfizer takes RSV vaccine candidate into Phase 3 trial

06-Sep-2021 By Rachel Arthur

Pfizer has launched a phase 3 trial for its investigational vaccine against respiratory syncytial virus (RSV) in adults aged 60+.

GlaxoSmithKline takes RSV maternal vaccine candidate into Phase 3 study

24-Nov-2020 By Rachel Arthur

GlaxoSmithKline has started dosing patients in a Phase 3 clinical program investigating the safety and efficacy of its Respiratory Syncytial Virus (RSV) candidate vaccine for maternal immunisation.

Bavarian Nordic warns COVID-19 may delay plans for RSV vaccine

27-Aug-2020 By Nick Taylor

Bavarian Nordic weighs options for RSV vaccine amid concerns COVID-19 response will drive down prevalence of pathogen.

AstraZeneca sells US rights to RSV drug for $1.5bn

14-Nov-2018 By Maggie Lynch

AstraZeneca announced it will sell US rights to Synagis to Sobi, to focus on its collaborative RSV therapy.